(ivonescimab)
(100 mg)
(one)
(Фл)
Ivonescimab 100 mg, experimental
Article:
In Stock
Ivonescimab is indicated for locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) in patients who have experienced disease progression following treatment with EGFR tyrosine kinase inhibitors (TKIs)
-
Сhemical name:ivonescimab
-
Dosage:100 mg
-
Quantity:one
-
Release form:Фл
No reviews yet